logo Hematology/Oncology Research Studies: Open for Enrollment Date: 01/16/20


Risk adapted, response based trial of nivolumab and brentuximab vedotin followed by brentuximab vedotin and bendamustine for pediatric and young adults with relapsed or refractory CD30 positive classic Hodgkin lymphoma

NCT#/Phase: NCT02927769
Phase 2
IRB#: 2017-049
Description: This is a Phase 2, open-label study of nivolumab + brentuximab (N+Bv) for children and young adults with relapsed/refractory cHL (Classic Hodgkin Lymphoma). There are 2 cohorts: one with participants at low risk relapse (R1 cohort), and one with participants at standard risk relapse (R2 cohort).
Inclusion: Individuals who are between 5 and 30 years of age with pathologically confirmed cHL excluding nodular lymphocyte-predominant HL, after failure or non-response to first-line therapy.
Enrollment Status: Open for enrollment
Sponsor: Children's Oncology Group
Principal Investigator(s): Carla Golden, MD
Contact(s): Rhodeza Salisi (510-428-3885 x 4761)
Diane Olzewski (510-428-3885 x 3246)
Diane Olszewski (510-428-3885 x 3246)
Study Link: https://clinicaltrials.gov/ct2/show/study/NCT02927769

UCSF Benioff Children's Hospital Oakland • 747 52nd Street, Oakland, California 94609 &bull Phone: (510) 428-3000